To fulfill our mission as a Corporate Venture Capital,
OVI prioritizes to make investment in novel startups possessing products and platforms potentially
with high synergy to R&D of our parent company, Ono Pharmaceutical Co.,Ltd. .
As a pioneer in cancer immunotherapy, Ono Pharmaceutical Co.,Ltd. takes advantage of its experience, technology and knowhow, nurtured through R&D of the immune checkpoint inhibitor OPDIVO, toward discovering innovative anticancer drugs beyond OPDIVO.
Based on the long-year experience of immunology research which has helped create OPDIVO, Ono Pharmaceutical Co.,Ltd. keeps research capabilities with a primary focus on biopharmaceutical development in immunology, working toward drug discovery in both areas of cancer immunotherapy and autoimmune therapy.
In the Neurology area, Ono Pharmaceutical Co.,Ltd. is prioritizing its research in biology of Glial cells, which maintain and support the environment necessary for survival and functional expression of neurons. Drug discovery based on human evidence would bring patients disease-modifying therapies, as well as symptomatic treatments for neurodegenerative disease, mental illness or chronic pain.
"Specialty" research at Ono Pharmaceutical Co.,Ltd. is research activity for clinically valuable pharmaceutical products for diseases for which treatment is in high unmet needs, free from the disease field. Drug discoveries with the understanding of pathogenesis will be a key for success in "Specialty" research.